Allogene Therapeutics Dividends
| ALLO Stock | USD 1.83 0.08 4.19% |
As of the 19th of December 2024, Dividend Paid And Capex Coverage Ratio is likely to grow to -148.98. Allogene Therapeutics' past performance could be the main factor of why investors trade Allogene Therapeutics stock today. Investors should clearly understand every aspect of the Allogene Therapeutics dividend schedule, including its future sustainability, and how it might impact an overall investment strategy. This tool is helpful to digest Allogene Therapeutics' dividend schedule and payout information. Allogene Therapeutics dividends can also provide a clue to the current valuation of Allogene Therapeutics.
| Last Reported | Projected for Next Year | ||
| Dividend Paid And Capex Coverage Ratio | (156.82) | (148.98) |
Allogene Therapeutics Quarterly Total Cash From Financing Activities |
|
Allogene |
Investing in stocks that pay dividends is one of many strategies that are good for long-term investments. Ex-dividend dates are significant because investors in Allogene Therapeutics must own a stock before its ex-dividend date to receive its next dividend.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allogene Therapeutics. If investors know Allogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allogene Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.55) | Quarterly Revenue Growth (0.27) | Return On Assets (0.26) | Return On Equity (0.54) |
The market value of Allogene Therapeutics is measured differently than its book value, which is the value of Allogene that is recorded on the company's balance sheet. Investors also form their own opinion of Allogene Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Allogene Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allogene Therapeutics' market value can be influenced by many factors that don't directly affect Allogene Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Allogene Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Allogene Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allogene Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.